COPD Drug Market Analysis & Forecasts 2024-2033: High Unmet Needs & Late-Stage Therapies

New Report: COPD Drug Market Analysis and Forecast (2024-2033)

ResearchAndMarkets.com has released the report “COPD: Seven-Market Drug Forecast and Market Analysis,” detailing the COPD drug market across seven major regions: the US, France, Germany, Italy, Spain, the UK, and Japan (7MM). This report includes an Excel-based forecast model projecting market trends through 2033.

The COPD market is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2023 to 2033. In 2023, the market was valued at $11.5 billion, with the US representing 79.4% of the total. The 5EU accounted for 17.5% ($2.0 billion), while Japan’s market was estimated at $361 million (3.1%).

By 2033, the COPD market is projected to reach $30.8 billion, with the US still dominating at 78.9% ($24.3 billion). The UK is forecasted to grow the fastest during this period, achieving a market value of $854 million at a CAGR of 15.3%.

Key Growth Drivers:

  • Introduction of Biologics: New anti-eosinophilic biologics like Sanofi and Regeneron’s Dupixent will contribute to sales growth, despite targeting a niche patient population.
  • Updated GOLD Guidelines: Revisions to the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) guidelines will promote increased use of inhaled corticosteroid/long-acting beta2-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) triple therapies.
  • Rising Awareness: Increased awareness of COPD will lead to more patients receiving treatment.

Challenges:

  • Shifts in Prescriptions: The new GOLD guidelines may decrease prescriptions for ICS/LABA therapies.
  • Inhaler Price Caps: Pharmaceutical companies implementing price caps on bronchodilators may reduce overall sales.
  • Patient Compliance Issues: Inhaler therapy compliance may decline due to complex administration schedules.

Report Highlights:

  • PDF report and Excel-based forecast model
  • Comprehensive analysis of the 7MM
  • Market insights and trends from 2023-2033

Why Buy This Report?

  • Develop in-licensing and out-licensing strategies by reviewing pipeline products.
  • Understand key trends shaping the COPD therapeutics market.
  • Identify emerging players and potential partnerships.

Key Topics Covered:

  1. Executive Summary
  2. Introduction
  3. Disease Overview
  4. Epidemiology
  5. Disease Management
  6. Current Treatment Options
  7. Unmet Needs
  8. R&D Strategies
  9. Pipeline Assessment
  10. Current and Future Players

Featured Companies:

  • Sanofi
  • Regeneron
  • GSK
  • AstraZeneca
  • Verona Pharma

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter